市場調查報告書

抗癲癇藥的全球市場:市場規模、佔有率、預測、機會分析 - 各世代、給藥途徑、流通管道、地區

Anti-epileptic Drugs Market: by Generation, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

出版商 Coherent Market Insights 商品編碼 931956
出版日期 內容資訊 英文 201 Pages
商品交期: 2-3個工作天內
價格
抗癲癇藥的全球市場:市場規模、佔有率、預測、機會分析 - 各世代、給藥途徑、流通管道、地區 Anti-epileptic Drugs Market: by Generation, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
出版日期: 2020年03月30日內容資訊: 英文 201 Pages
簡介

癲癇,是所有年齡層的人罹患的非傳染性的腦慢性疾病。根據全世界的癲癇盛行率的上升預計促進抗癲癇藥市場成長。根據世界衛生組織(WHO)的報告,2019年的全球癲癇的罹患數估計為約5,000萬人,是全世界最常見的神經疾病之一。

本報告提供全球抗癲癇藥市場調查,市場概要,各世代、給藥途徑、流通管道、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查目的與假設

  • 調查目的
  • 假設
  • 簡稱

第2章 市場展望

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場片段:各世代
    • 市場片段:各給藥途徑
    • 市場片段:各流通管道
    • 市場片段:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態、規定、趨勢分析

  • 市場動態
    • 市場成長要素
    • 市場阻礙因素
    • 市場機會
  • 影響分析
  • 醫藥品開發與發展
  • 法規方案
  • 研究開發支援的舉措
  • 抗癲癇藥的包裝相關法規
  • 抗癲癇藥多樣的包裝解決方案
  • 主要的焦點
  • 開發平台分析
  • PEST分析
  • 流行病學

第4章 全球抗癲癇藥市場:各世代

  • 簡介
  • 第1代藥
  • 第2代藥
  • 第3代藥

第5章 全球抗癲癇藥市場:各給藥途徑

  • 簡介
  • 口服給藥
  • 經靜脈給藥

第6章 全球抗癲癇藥市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第7章 全球抗癲癇藥市場:各地區

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第8章 競爭情形

  • 企業簡介
    • Novartis AG
    • GlaxoSmithKline Plc
    • Johnson & Johnson Service, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • Sanofi S.A.
    • 大日本住友製藥
    • Mylan N.V.
    • Bausch Health Companies Inc.
    • UCB S.A.

第9章 章節

  • 參考資料
  • 調查手法
  • 關於Coherant Market Insights
目錄

Epilepsy is associated with disrupted activities in the brain known as seizures, which affects the central nervous system. Epilepsy is categorized into generalized seizures and partial seizures based on the areas affected in the brain. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Seizures are further classified into mild seizures and stronger seizures depending on the severity of the seizures. The diagnosis of mild seizures are difficult, as its lasts only for few seconds. Stronger seizures may last for a few seconds to several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure.

Market Dynamics

Epilepsy is a chronic non-communicable disease of the brain that affects people of all ages. The increasing prevalence of epilepsy across the globe is expected to drive growth of the anti-epileptic drugs market over the forecast period. For instance, according to the World Health Organization (WHO) report of 2019, around 50 million people worldwide suffered from epilepsy, making it one of the most common neurological diseases, globally.

Furthermore, epilepsy has high prevalence among the pediatric population. For instance, according to the American Academy of Pediatrics data published in April 2017, epilepsy affects 0.5% to 1% of children globally and is the most frequently occurring chronic neurologic condition in childhood.

Around one-third of children with epilepsy can be assigned to a specific epilepsy syndrome, as defined by the most recently proposed system for organization of epilepsy syndrome. Moreover, according to the Society of Neuroscience, in 2015, epilepsy affected around 10.5 million children, worldwide, and the types and severity of the disorder varied significantly. The common cause of epilepsy includes brain damage due to tumors, Infectious diseases such as meningitis, genetic conditions, and lack of oxygen to the brain at birth.

However, side effects of drugs is major restraining factor for anti-epileptic drugs market growth, which is expected to hamper the market growth over the forecast period. For instance, according to the Journal of Family Practice the side effects of anti-epileptic drugs such as Phenytoin, which causes a pattern of defects collectively called Fetal Hydantoin Syndrome (FHS) characterized by variable degrees of hypoplasia and ossification of the distal phalanges and craniofacial abnormalities. Moreover, Phenobarbital has been associated with an increase in congenital defects when used for epilepsy, but not for other indications.

A syndrome associated with Carbamazepine results in minor craniofacial defects, fingernail hypoplasia, and developmental delay. Moreover, this drug may cause neural-tube defects (NTDs). Carbamazepine, Phenytoin, Primidone, and Phenobarbital affect folate metabolism or absorption, and this may increase the risk of birth defects, including NTDs.

Key features of the study:

This report provides in-depth analysis of the global anti-epileptic drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%) for the forecast period, 2020-2027, considering 2019 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players

It profiles key players in the global anti-epileptic drugs market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies

Key players covered as a part of this study include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Mylan N.V., Bausch Health Companies Inc., and UCB Pharma Limited

Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological upgradation, market expansion, and marketing tactics

The global anti-epileptic drugs market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers for global anti-epileptic drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Anti-epileptic Drugs Market, by Generation:
  • First Generation
  • Second Generation
  • Third Generation
  • Global Anti-epileptic Drugs Market, by Route of Administration:
  • Oral
  • Intravenous
  • Global Anti-epileptic Drugs Market, by Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Anti-epileptic Drugs Market, by Region:
  • North America
  • By Country:
  • U.S.
  • Canada
  • By Generation:
  • First Generation
  • Second Generation
  • Third Generation
  • By Route of Administration:
  • Oral
  • Intravenous
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Europe
  • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • By Generation:
  • First Generation
  • Second Generation
  • Third Generation
  • By Route of Administration:
  • Oral
  • Intravenous
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Asia Pacific
  • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • By Generation:
  • First Generation
  • Second Generation
  • Third Generation
  • By Route of Administration:
  • Oral
  • Intravenous
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Latin America
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • By Generation:
  • First Generation
  • Second Generation
  • Third Generation
  • By Route of Administration:
  • Oral
  • Intravenous
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Middle East
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • By Generation:
  • First Generation
  • Second Generation
  • Third Generation
  • By Route of Administration:
  • Oral
  • Intravenous
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Africa
  • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
  • By Generation:
  • First Generation
  • Second Generation
  • Third Generation
  • By Route of Administration:
  • Oral
  • Intravenous
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Company Profiles
  • Novartis AG *
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • GlaxoSmithKline Plc
  • Johnson & Johnson Service, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • SANOFI S.A.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Mylan N.V.
  • Bausch Health Companies Inc.
  • UCB S.A.
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Generation
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Drug Development and Evolution
  • Regulatory Scenario
  • Epilepsy Initiatives Supporting R&D
  • Packaging Requirements for Epilepsy Drugs
  • Various Packaging Solutions for Epilepsy Drugs
  • Key Highlights
  • Pipeline Analysis
  • PEST Analysis
  • Epidemiology

4. Global Anti-epileptic Drugs Market, By Generation, 2019 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • First Generation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Second Generation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Third Generation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

5. Global Anti-epileptic Drugs Market, By Route of Administration, 2019 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Anti-epileptic Drugs Market, By Distribution Channel, 2019 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Anti-epileptic Drugs Market, By Region, 2019 - 2027 (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Generation, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Generation, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Generation, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Generation, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Generation, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Generation, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • GCC
    • Countries
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Novartis AG *
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Johnson & Johnson Service, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Mylan N.V.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bausch Health Companies Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • UCB S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact